After taking expert advice from world class toxicology and DMPK experts, OncoTherics has commenced an innovative DMPK equivalence programme. The close chemical relationship between OCT1002 …

Read more

GMP scale up development has been completed for OCT1002 and OCT1004. The synthesis route has been re-designed for both assets to ensure ready supply of …

Read more

OncoTherics second annual general meeting was held on 30th June 2023 and the FY2022 audited accounts were approved. The company looks forward to progressing its …

Read more

OncoTherics held its first AGM as a SPOŁKA AKCYJNA on 29th June 2022 in Warsaw, Poland. The Auditors report was presented alongside the 2021 consolidated …

Read more

ITPP (Myo-lnositol trispyrophosphate) is a natural phosphosugar derivative – well known for its ability to trigger the dissociation of molecular oxygen from haemoglobin. Experimental studies …

Read more

OncoTherics has successfully raised 2.32M PLN in first round funding from founders and Polish investors to leverage 5M PLN of Polish regional grant funding. The …

Read more

OncoTherics Poland has today successfully transformed from a Spółka z ograniczoną odpowiedzialnością (Sp. z o.o) to a Spółka akcyjna (S.A.) company as part of a …

Read more

OncoTherics CEO, Stefan Ogrodzinski, is due to showcase OncoTherics’ novel drug technology at the upcoming GPWInnovation day, sponsored by Trigon. The online conference aims to …

Read more

OncoTherics’ CEO, Stefan Ogrodzinski, will be presenting a short session about the UK biotech/life sciences ecosystem. The talk will compare the UK ecosystem to the …

Read more

The high-profile event will also recognise the award of the Nobel prize to Professor Robert Huber for his seminal works on hypoxia. Prof. Zbigniew Madeja, …

Read more